Evidence map›Paper›PMID 29748853›Full record

ArticleMolecular diversity2018

Systematic search for benzimidazole compounds and derivatives with antileishmanial effects.

Juan Carlos Sánchez-Salgado, Pablo Bilbao-Ramos, María Auxiliadora Dea-Ayuela, Francisco Hernández-Luis, Francisco Bolás-Fernández, José L Medina-Franco, Yareli Rojas-Aguirre

Abstract read
PubMed Publisher
In one paragraph

Article in Molecular diversity, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
0.9field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 13 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Review
  8. Review
  9. SystematicFrontiers in chemistry · 2021
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 4 institutions in 2 countries.

Juan Carlos Sánchez-SalgadoInstituto de Medicina Molecular y Ciencias Avanzadas, Rayo 11 Jardines del Pedregal, Álvaro Obregón, 01900, Mexico City, Mexico.
Pablo Bilbao-RamosDepartamento de Parasitología, Facultad de Farmacia, Universidad Complutense de Madrid, Plaza Ramón y Cajal s/n, 28040, Madrid, Spain.
María Auxiliadora Dea-AyuelaDepartamento de Farmacia, Universidad CEU Cardenal Herrera, s/n, 46113, Moncada, Valencia, Spain.
Francisco Hernández-LuisFacultad de Química, Departamento de Farmacia, Universidad Nacional Autónoma de México, 04510, Mexico City, Mexico.
Francisco Bolás-FernándezDepartamento de Parasitología, Facultad de Farmacia, Universidad Complutense de Madrid, Plaza Ramón y Cajal s/n, 28040, Madrid, Spain.
José L Medina-FrancoFacultad de Química, Departamento de Farmacia, Universidad Nacional Autónoma de México, 04510, Mexico City, Mexico.
Yareli Rojas-AguirreFacultad de Química, Departamento de Farmacia, Universidad Nacional Autónoma de México, 04510, Mexico City, Mexico. yarelirojas@gmail.com.ORCID http://orcid.org/0000-0001-5650-8637
Universidad Complutense de Madrid · ESUniversidad Nacional Autónoma de México · MXSecretaría de Ciencia, Humanidades, Tecnología e Innovación · MXUniversidad Cardenal Herrera CEU · ES

Funding

Agencia Española de Cooperaciín Internacional para el Desarrollo AP/0397670/11Consejo Nacional de Ciencia y Tecnología Ph.D mixed scholarship grant 290618Consejo Nacional de Ciencia y Tecnología Ph.D. scholarship 211321Facultad de Química, UNAM Programa de Apoyo a la Investigación y el Posgrado PAIP 5000-9157Facultad de Química, UNAM Programa de Apoyo a la Investigación y el Posgrado (PAIP) grant 5000-9163
6 · The paper itself

Abstract

Leishmaniasis is a neglected tropical disease that currently affects 12 million people, and over 1 billion people are at risk of infection. Current chemotherapeutic approaches used to treat this disease are unsatisfactory, and the limitations of these drugs highlight the necessity to develop treatments with improved efficacy and safety. To inform the rational design and development of more efficient therapies, the present study reports a chemoinformatic approach using the ChEMBL database to retrieve benzimidazole as a target scaffold. Our analysis revealed that a limited number of studies had investigated the antileishmanial effects of benzimidazoles. Among this limited number, L. major was the species most commonly used to evaluate the antileishmanial effects of these compounds, whereas L. amazonensis and L. braziliensis were used least often in the reported studies. The antileishmanial activities of benzimidazole derivatives were notably variable, a fact that may depend on the substitution pattern of the scaffold. In addition, we investigated the effects of a benzimidazole derivative on promastigotes and amastigotes of L. infantum and L. amazonensis using a novel fluorometric method. Significant antileishmanial effects were observed on both species, with L. amazonensis being the most sensitive. To the best of our knowledge, this chemoinformatic analysis represents the first attempt to determine the relevance of benzimidazole scaffolds for antileishmanial drug discovery using the ChEMBL database. The present findings will provide relevant information for future structure-activity relationship studies and for the investigation of benzimidazole-derived drugs as potential treatments for leishmaniasis.

Indexed as

Antiprotozoal AgentsBenzimidazolesDrug Evaluation, PreclinicalLeishmaniaStructure-Activity RelationshipAntiprotozoal AgentsBenzimidazolesBenzimidazolesChemoinformaticsLeishmaniaMolecular scaffold

Identifiers

PMID29748853
OpenAlexW2802142363

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.